3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Classical hematology
33
Thoracic
4
Plasma cell
3
Genitourinary
2
Gastrointestinal
2
CNS
2
Sarcoma
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Colorectal Neoplasms
1432
Pancreatic Neoplasms
860
Carcinoma, Hepatocellular
743
Stomach Neoplasms
647
Colonic Neoplasms
447
Rectal Neoplasms
404
Esophageal Neoplasms
398
Breast Neoplasms
331
Carcinoma, Non-Small-Cell Lung
326
Neoplasms
307
Liver Neoplasms
282
Cholangiocarcinoma
244
Ovarian Neoplasms
243
Lung Neoplasms
237
Neoplasm Metastasis
235
Gastrointestinal Neoplasms
217
Melanoma
185
Prostatic Neoplasms
166
Esophageal Squamous Cell Carcinoma
166
Biliary Tract Neoplasms
161
Endometrial Neoplasms
143
Uterine Cervical Neoplasms
130
Squamous Cell Carcinoma of Head and Neck
129
Carcinoma, Renal Cell
114
Head and Neck Neoplasms
113
Sarcoma
100
Urinary Bladder Neoplasms
97
Adenocarcinoma Of Esophagus
90
Triple Negative Breast Neoplasms
86
Anus Neoplasms
83
Interventions
isoquercitrin
1
abelacimab
1
MAA868
1
Dalteparin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Venous Thromboembolism
×
Gastrointestinal
×
1 year
×
Clear all
NCT05171075
2026-04-17
MAGNOLIA
Anthos Therapeutics, Inc.
Phase 3
Terminated
417 enrolled
NCT06861088
2026-02-02
CATIQ P3
Quercis Pharma AG
Phase 3
Recruiting
480 enrolled